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Abstract
In the intestine a balance between proinflammatory 
and repair signals of the immune system is essential for 
the maintenance of intestinal homeostasis. The innate 
immunity ensures a primary host response to microbial 
invasion, which induces an inflammatory process to lo-
calize the infection and prevent systemic dissemination 
of pathogens. The key elements of this process are the 
germline encoded pattern recognition receptors inclu-
ding Toll-like receptors (TLRs). If pathogens cannot 
be eliminated, they may elicit chronic inflammation, 
which may be partly mediated via  TLRs. Additionally, 
chronic inflammation has long been suggested to trig-
ger tissue tumorous transformation. Inflammation, the 
seventh hallmark of cancer, may affect all phases of 
tumor development, and evade the immune system. 
Inflammation acts as a cellular stressor and may trigger 
DNA damage or genetic instability. Furthermore, chro-
nic inflammation can provoke genetic mutations and 
epigenetic mechanisms that promote malignant cell 
transformation. Colorectal cancers in inflammatory bo-
wel disease patients are considered typical examples of 
inflammation-related cancers. Although data regarding 
the role of TLRs in the pathomechanism of cancer-as-
sociated colitis are rather conflicting, functionally these 
molecules can be classified as ”largely antitumorigenic” 
and ”largely pro-tumorigenic” with the caveat that the 
underlying signaling pathways are mainly context (i.e. , 
organ-, tissue-, cell-) and ligand-dependent.
© 2014 Baishideng Publishing Group Inc. All rights reserved.
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Core tip: Colorectal cancers arising in inflammatory bo-
wel disease patients are considered typical examples of 
inflammation-associated cancers. The exact role of Toll-
like receptor (TLR)-signaling in colitis-associated can-
cer initiation and development is conflicting. Here we 
aimed to summarize recent data on the contribution of 
TLR-mediated immune responses to inflamation-related 
colonic carcinogenesis. 
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INTRODUCTION
Crohn’s disease (CD) and ulcerative colitis (UC), the main 
clinical phenotypes of  idiopathic, relapsing-remitting in-
flammatory bowel disease (IBD) are systemic disorders 
affecting the GI-tract with frequent extraintestinal mani-
festations and other associated autoimmune conditions. 
IBD is considered a polygenic autoimmune disorder with 
a complex multifactor etiology. Generally, IBD arises in 
susceptible individuals in whom upon an environmental 
trigger a sustained disturbed, deleterious mucosal im-
mune reaction is provoked towards commensal micro-
biota[1].
A balance between proinflammatory and repair sig-
nals of  the immune system is essential for the mainte-
nance of  intestinal homeostasis. The interplay of  genes 
regulating immune functions is strongly affected by the 
environment, especially gut resident microbiota. On the 
basis of  genetic alterations in CD, impaired sensing and 
handling of  intracellular bacteria by the innate immunity 
seem to be one of  the most relevant pathophysiologic 
features[1]. 
The innate immunity ensures a primary host response 
to microbial invasion, which induces an inflammatory 
process to localize the infection and prevent systemic dis-
semination of  pathogens. The key elements of  this pro-
cess are the germline encoded pattern recognition recep-
tors (PRRs) including Toll-like receptors (TLRs), NOD-
like receptors (NLRs), ribonucleic-acid (RNA) helicases, 
C-type lectin receptors, and cytosolic deoxyribonucleic-
acid (DNA) sensors, which sense evolutionarily con-
served pathogen-associated molecular patterns (PAMPs) 
of  microbiota. The detection of  PAMPs by PRRs trig-
gers sequential activation of  intracellular signaling path-
ways resulting in induction of  a wide range of  cytokines 
and chemokines that unite the early host response to 
infection[2]. If  pathogens cannot be eliminated, they may 
elicit chronic inflammation, which may be partly medi-
ated via TLRs. Additionally, chronic inflammation has 
long been suggested to trigger tissue tumorous transfor-
mation. Indeed, a higher incidence of  intestinal cancers 
has been observed in IBD patients. However, the exact 
role of  TLR-signaling in colitis-associated cancer (CAC) 
initiation and development is still unknown, therefore, we 
aimed to summarize the currently available information 
on the contribution of  TLR-mediated immune responses 
to inflammation-related colonic carcinogenesis. 
RELATION OF TOLL-LIKE RECEPTORS TO 
COLONIC MUCOSA
The highly conserved TLRs represent sentinels of  the 
innate immune system. TLRs belong to the type 1 trans-
membrane glycoproteins, which contain extracellular 
leucin-rich repeated sequences and Toll/interleukin-1 
receptor (TIR) signaling domains. TLRs have five TIR-
containing adaptor proteins, Myeloid differentiation 
factor 88 (MyD88), MyD88 adaptor-like (TIRAP), TIR 
domain containing adaptor inducing interferon-β (TRIF), 
TRIF-related adaptor molecule (TRAM)[3], and sterile α 
and heat-armadillo motifs[4]. TLR4 was the first recep-
tor to be identified, and currently 10 TLRs have been 
identified in humans, and 13 in mice[5]. TLRs are mainly 
expressed in the cells of  the innate and adaptive immune 
system [i.e., monocytes, macrophages, lymphocytes, mast 
cells, dendritic cells (DCs)], however, all TLR1-9 have 
also been identified as being expressed in human intesti-
nal epithelial cells (IECs)[6-8]. 
TLRs usually recognize microbial wall components, 
as well as DNA and RNA fragments. TLRs bind spe-
cific motifs appearing in bacteria, fungi, protozoa, and 
viruses[9,10]. These motifs are mainly lipids and lipopep-
tides (TLR-1, -2, -4, -6), bacterial flagellin (TLR5), and 
nucleic acid fragments (TLR-3,-7, -8, -9). TLR3 binds 
double-stranded RNA from viruses, while TLR7 and -8 
can recognize single-stranded RNAs. Moreover, TLR7 
recognizes immunoglobulin/self-RNA complexes within 
autoimmune disease conditions. Imiquimod is a specific 
ligand for TLR7. TLR9 is activated by bacterial and viral 
DNA, immunoglobulin-DNA complexes, and synthetic 
oligodeoxynucleotides (ODNs), which contain unmethyl-
ated CpG sequences[9,10].
In vitro data have demonstrated hyporesponsiveness 
of  IECs to TLR ligands[7,8]. Antigen-presenting cells 
(APCs) in the lamina propria (LP) also seem to be unre-
sponsive to TLR ligands[11]. Under physiologic conditions, 
TLR3, -7, -8, and -9 are expressed in endosomes, or ba-
solateral membrane (TLR5), where these TLRs are not 
exposed to pathogens unless microbiota get into the cells 
or invade mucosa[2]. Apical epithelial TLR9 activation 
by bacterial DNA fragments has been reported to take 
part in colonic homeostasis[12]. These findings underline 
a unique feature of  TLRs (and other PRRs) in IECs that 
establishes immune tolerance to the commensal flora of  
the colonic mucosal interface. 
In addition, epithelial TLRs contribute to balancing 
the composition of  luminal microorganisms by regulat-
ing the secretion of  different antimicrobial peptides and 
mucosal IgA. TLR9-/- mice have impaired expression of  
cryptidin (α-defensin) compared to wild-type mice[12]. Sig-
naling through TLR-2, -3, and -4 have all been implicated 
with the expression of  β-defensins in IECs[13,14]. Several 
TLR signals in IECs induce B cell-activating factors lead-
ing to immunoglobulin class switch recombination in B 
cells of  the LP without T cell activation, resulting in IgA 
secretion[15]. Moreover, activation of  TLR-3 and -4 has 
been found to induce epithelial expression of  an epitheli-
al immunoglobulin transporter (polymeric immunoglobu-
lin receptor) that enhances luminal IgA secretion[16,17].
To date, TLR signaling can be classified into classical/
canonical and alternative/noncanonical pathways[18]. All 
TLRs, except TLR3, utilize the MyD88-dependent signal-
ing pathway to induce the expression of  proinflammatory 
cytokine genes[19]. TLR3 exclusively uses the TRIF path-
way[19]. The classical inflammatory signaling pathway is 
mainly activated through MyD88, which, in turn, recruits 
IRAKs and TRAF6[20]. TRAF6 activates transforming 
growth factor-β activated kinase 1 which phosphorylates 
and activates the inhibitor of  kappa light polypeptide 
gene enhancer in B-cells kinase complex, finally resulting 
in the release and translocation of  NF-κB into the nu-
cleus, thereby inducing the production of  tumor necrosis 
factor (TNF)-α, interleukin (IL)-1, and IL-6, the key 
mediators of  (intestinal) proinflammatory responses[21-23]. 
However, TLR3 and some of  the TLR4 signals utilize 
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the TRIF adaptor molecule signaling independently of  
MyD88. This alternative pathway culminates in the ac-
tivation of  TRAF3 and IRF3, resulting in the secretion 
of  type Ⅰ interferons (IFNs), even in the gut[24]. TLR4 
is unique among the TLRs as it can activate two distinct 
signaling pathways: the classical pathway (through TIRAP 
and MyD88) and the alternative pathway (via TRIF and 
TRAM)[18]. 
ASPECTS OF COLITIS-ASSOCIATED 
CANCER
As early as ancient times, Hippocrates and Galenus real-
ized the similarity between inflammation and cancer, and 
hypothesized that cancer evolved from inflammatory 
lesions[25]. In 1863, Rudolf  Virchow observed a close 
etiologic relation between chronic inflammation and 
carcinogenesis, realizing that tumors possess a typical 
“lymphoreticular infiltrate”[26,27]. The first evidence of  
the antitumoral effects of  microbial products dates to 
the beginning of  the 18th century, when Deider reported 
that infection in patients with cancer could be accompa-
nied by the remission of  malignancies[28]. In the 1890s, 
William B. Coley, a surgeon from New York, observed 
that repeated injections of  a mixture of  bacterial toxins 
served as an efficient antitumoral therapeutic agent[29]. 
Later, in 1943, lipopolysaccharide (LPS) was discovered 
as the “hemorrhage-producing fraction” of  Coley’s ly-
sate, which accounted for its antitumoral effects[28]. After 
the discovery of  TLRs, their ligands and signaling path-
ways, it was found that microbe-derived factors act by 
stimulating TLR signaling and activating both the innate 
and adaptive immune responses to enhance anti-tumor 
immunity[30]. 
In 2000, Hanahan and Weinberg[31] proposed a model 
to define the six hallmarks of  carcinogenesis. Generally, 
inflammation is required to fight microbial infections, 
heal wounds, and maintain tissue homeostasis, however, 
it can lead to cancer. Inflammation, the seventh hallmark 
of  cancer may affect all phases of  tumor development, 
including tumor initiation, promotion, invasion and 
metastatic dissemination, and can evade the immune 
system. Inflammation acts as a cellular stressor and may 
trigger DNA damage or genetic instability. Furthermore, 
chronic inflammation can provoke genetic mutations and 
epigenetic mechanisms which promote malignant cell 
transformation. Based on these results, nowadays increas-
ing evidence suggests that inflammation should also be 
included in this list[18,32]. In inflammation, a peculiar tissue 
microenvironment is induced with the capacity to tolerate 
tumor cell growth and metastasis by altering the immu-
noregulatory mechanism, and thus making the immune 
system incapable of  destroying tumor cells[18]. Moreover, 
the expression of  TLRs in tumor cells may directly or in-
directly contribute to tumorigenesis in several tissues and 
organs. Activation of  TLR signaling pathways may pro-
mote tumor invasion, apoptosis resistance, chemoresis-
tance, tumor progression and metastasis development[18]. 
In chronic inflammatory conditions, when organs 
with large epithelial surfaces are affected, as in IBD, the 
epithelial barrier function is critical for disease onset. As 
the epithelium is densely inhabited by resident microbial 
flora, the role of  native immunity is particularly impor-
tant in recognising and distinguishing commensal enteric 
bacteria from invading bacteria, and thus, in maintaining 
tolerance and homeostasis. Subsequently, the chronic un-
restrained inflammatory response which occurs in IBD is 
mainly driven by a disintegrated host immune regulatory 
network, and is further responsible for the increased sus-
ceptibility to colorectal cancer (CRC). 
TLRs are involved in the maintenance and function-
ing of  the epithelial barrier integrity in the gut and regu-
lating the MyD88 adaptor protein. Therefore, TLRs may 
display a protective function in the control of  intestinal 
inflammation and inflammation-associated cancer[33]. 
Colorectal cancers in IBD patients are considered typi-
cal examples of  inflammation-related cancers. However, 
tumors usually appear after several years of  active dis-
esase, with a cumulative lifetime risk of  18%-20% in UC, 
and up to 8% in CD[34-36]. Indeed, recent epidemiological 
data indicate that over 25% of  all cancers are related to 
chronic infection and other unresolved inflammation[37]. 
Current results indicate that TLRs have a potential role in 
microbiota-associated gastrointestinal cancer metastasis 
through the recognition of  microbiota ligands, initiating 
inflammation, and promoting tumorigenesis[38].
Most colorectal cancers are sporadic without any 
obvious connection to intestinal inflammation. Interest-
ingly, IBD patients also have an increased susceptibility 
to other malignancies, such as lymphomas/leukemias and 
hepatocellular carcinoma suggesting that local inflam-
mation could not only have intestinal, but also systemic 
tumor-promoting effects, or the genetic alterations that 
affect inflammatory and immune homeostasis in IBD 
also predispose patients to cancer in other tissues[39,40]. In 
IBD, the increased susceptibility to extraintestinal tumors 
could also be related to immunosuppressive treatment. 
However, the types of  tumors increasingly found in IBD 
patients are different from those observed in transplant 
patients under immunosuppression[41,42]. 
Both intrinsic and extrinsic inflammatory pathways 
are linked to carcinogenesis. Intrinsic inflammation is 
mainly initiated by mutations leading to oncogene activa-
tion as well as to inactivation of  tumor suppressors. The 
extrinsic pathway in terms of  infection or inflammation 
increases cancer risk. Although in IBD patients inflamed 
intestinal cells already have CRC-related genetic abnor-
malities before developing dysplasia, in CAC, genetic 
alterations seem only to be a secondary cause rather than 
a primary cause of  carcinogenesis[43]. It is likely that ab-
normalities in PRR signaling lead to dysregulated expres-
sion of  genes and enzymes involved in cell proliferation, 
apoptosis, and DNA repair prior to gene alterations. Fre-
quent alternative cycles of  mucosal injury and repair in 
the presence of  tumorigenic cytokines, chemokines, and 
prostaglandins may also predispose to genetic mutations, 
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ma cell lines, HCT15, SW620 or HT29[55-57]. TLR expres-
sion in tumor cells appears to promote tumorigenesis by 
facilitating survival and migration in a tumorous microen-
vironment that is characterized by chronic inflammation 
and PAMPs[58]. On the other hand, the complicated inter-
actions among tumor cells, immune cells, and PAMPs/
DAMPs in the tumorous microenvironment may support 
an inappropriate immune response or antitumor immune 
tolerance through TLR signaling. With regard to tumori-
genesis, a typical dual role of  TLR signaling pathways 
has been proposed, as they may be critical for cancer cell 
survival and progression, however they may also elicit 
tumor death signaling. TLR-mediated signaling is directed 
toward cytoprotection or tumor cell suppression, thus the 
pro-survival or pro-death function is context-dependent, 
and influenced by many intra- and extracellular factors, 
such as the involved tissues, surrounding microenviron-
ment, genetic background, and stage of  tumor develop-
ment, nevertheless its precise relation to cancer networks 
has not yet been fully elucidated[18]. 
Toll-like receptor-mediated anti-tumorigenic effects
During the past two decades, studies have established 
that boosting TLRs and downstream mediators such as 
type Ⅰ IFNs, can be used therapeutically to shift the bal-
ance from immunotolerance to antitumoral effects[59]. 
The antigen-presenting capacity of  tumor cells is 
poor, therefore, antitumoral immune responses usually 
depend on professional APCs like DCs[60]. DCs have 
been a focus of  cancer research due to their ability to ini-
tiate potent antitumoral immune responses. A lack of  DC 
activation, often resulting from inhibitory signals from 
cancer cells, may also induce immune tolerance via T cell 
deletion or regulatory T cells (Tregs)[60], which favors 
tumor progression. TLR-activated DCs can mediate an-
titumoral responses through antigen presentation, T cell 
activation, and direct cytotoxic effects on tumor cells[61,62]. 
which increase cancer risk[44,45]. 
The definite similarities between tumor stroma and 
chronic wounds have led to the suggestion that cancers 
are wounds that do not heal, leading finally to uncon-
trolled tissue repair processes[46] (Figure 1). CRC arises 
from the intestinal epithelium, a highly proliferative tis-
sue which renews itself  every several days under steady-
state conditions. Repeated or prolonged wound repair 
responses to tissue injury may provoke malignant cell 
transformation[47]. Epithelial regeneration and myofibro-
blast activation, two major events in wound-healing, are 
strongly influenced by TLR signaling. The contribution 
of  TLR signals to regeneration can be found in the intes-
tine, where a TLR2/TLR4/MyD88 cascade mediates mu-
cosal healing in the regenerative phase of  DSS-colitis[48,49]. 
It has also been reported that TLR-mediated MyD88 sig-
naling in macrophages of  the LP regulate crypt stem cell 
differentiation and epithelial proliferation through cyclo-
oxygenase-2 and prostaglandin (PG)E2 expression[49,50]. 
TLR4 activation has also been shown to induce IEC pro-
liferation via induction of  EGFR ligands[51,52]. Moreover, 
in inflammatory circumstances the surface expression of  
TLR-2 and -4 may be enhanced leading to IECs respon-
siveness to their ligands[53,54]. Based on these results, it 
seems that abnormal TLR signaling may induce enhanced 
epithelial proliferation, and thus may contribute to colitis-
associated carcinogenesis. 
TOLL-LIKE RECEPTORS IN COLITIS-
ASSOCIATED CANCER
Previous studies have shown that certain TLRs are ex-
pressed in colon cancers and colon cancer cell lines[18]. 
In colorectal cancers, TLR3, -4, -5, -7, and -8 have been 
found to be expressed[18], while several TLRs (including 
TLR7-9) are also expressed in the human colon carcino-
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Figure 1  Relationship between pattern recognition receptors and tissue regeneration. In case of acute tissue injury, TLRs acts as mucosal healing factors. In 
the case of chronic, sustained inflammation, TLRs may promote dysregulated wound healing leading to cancer development. PRRs: Pattern recognition receptors; 
TLRs: Toll-like receptors; IFNs: Interferons; TGF: Transforming growth factor; PDGF: Platelet-derived growth factor.
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TLR5 activation on DCs as well as TLR9-stimulated plas-
mocytoid DCs promote antitumoral immunity[63,64]. It is 
hypothesized that DC-mediated tumor cell killing triggers 
a more efficient antigen presentation to cytotoxic T cells, 
thus amplifying antitumoral responses. 
Activation of  TLRs on DCs regulates T cell activa-
tion not only via the class Ⅱ major histocompatibility 
complex and co-stimulatory molecules, but also through 
TLR-induced signals in DCs that block the suppressive 
effect of  regulatory T cells in an IL-6-dependent man-
ner[65]. Moreover, TLR8 activation can directly inhibit 
Treg function, hence support antitumoral immunity[66]. 
TLR9 agonists as well as TLR-induced IFNα also have 
an important role since both are known to reduce tumor 
growth by blocking angiogenesis[67,68]. 
In a recent study, the colonic tumor development 
modulatory effect of  TLR5-dependent signaling was 
assayed in a mouse xenograft model of  human colon 
cancer[69]. The lack of  MyD88 or TLR5 expression was 
found to enhance tumor growth and inhibit tumor necro-
sis. In contrast, TLR5 activation by peritumoral flagellin 
treatment substantially increased tumor necrosis, leading 
to significant tumor regression. 
Within the TLR family, TLR9 is specifically stimulated 
upon sequence- and methylation-dependent DNA signal-
ing. Self-DNA and oligonucleotides containing unmeth-
ylated CpG motifs are also sensed by and activate TLR9. 
Modifications in the structure of  nucleic acids influence 
their immunomodulatory, i.e., agonistic or suppressive, as 
well as pro- or anti-tumorigenic capacity[57,70]. TLR9 acti-
vation by synthetic oligodeoxynucleotide agonists (CpG-
ODN) has also demonstrated antitumor activity in xeno-
graft models of  murine colon cancer[71]. Moreover, TLR9 
agonists induce type Ⅰ IFN secretion in DCs finally 
resulting in cytotoxic DCs, activated NK cells and cyto-
toxic T cells, all of  which possess a remarkable antitumor 
immune response[72,73]. 
Toll-like receptor-mediated pro-tumorigenic effects
TLRs may act as tumor promoting factors by transmit-
ting proinflammatory, anti-apoptotic, proliferative or pro-
fibrogenic signals in either the tumor cells or the tumor-
ous microenvironment.
TLRs are key elements of  inflammatory signaling which 
can be mediated by MyD88-dependent and MyD88-
independent pathways. Enhancement of  the signaling 
pathway of  transcription factor nuclear factor (NF)-κB 
is one of  the major tumor-promoting effects of  TLRs. 
TLR activation upregulates several tumorigenic inflam-
matory cytokines (e.g., IL-1β, TNFα, IL-6) in a NF-κB-
dependent manner[59,74,75]. which transcriptionally controls 
a large set of  target genes that play important roles in cell 
survival, inflammation, and immune responses[76]. 
TLR signaling is also involved in the inhibition of  
apoptosis. NF-κB is considered an important anti-
apoptotic pathway controlling the expression of  anti-
apoptotic genes and restricting the activation of  pro-
apoptotic pathways[77,78]. TLR signaling can activate NF-
κB through MyD88-dependent and MyD88-independent 
pathways, moreover, the TLR-mediated release of  IL-
1β and TNFα promotes NF-κB activation. In colorectal 
cancer, TLR-induced NF-κB activation has been found 
to facilitate tumor cell survival[48]. Furthermore, in the 
MC26 mouse colon cancer cell line TLR4 activation was 
found to mediate resistance of  tumor cells to cytotoxic T 
cell-mediated cell death and favor tumor growth[55]. 
The TLR-mediated promotion of  wound healing may 
also lead to cancer development. After DSS-mediated in-
jury, TLR2 and TLR4 activation facilitates epithelial repair 
via the MyD88-dependent pathway[48], and TLR-MyD88 
signaling also regulates the expression of  epiregulin, 
which may contribute to colon cancer development[78]. 
In mice, Faubion et al[79] demonstrated that chronic 
inflammation arising from the bowel may induce thymic 
involution and Treg cell suppression. These events are 
suggested to lead to the enhancement of  inflammation-
mediated processes, and worsen IBD. Restoration of  ho-
meostasis through suppression of  TNFα production and 
fortification of  Treg cells were proposed for the treatment 
of  human IBD[80]. In the existing connection between 
TLR-signaling and Treg cells[65,81], these data on IBD may 
support the concept that uncontrolled inflammation 
weakens the Treg-mediated inhibition and increases the 
risk for inflammation-associated carcinogenesis. 
Controversial data exist regarding the role of  TLR2 
in CAC. In one study, increased tumor development and 
higher IL-6, IL-17A and phospho-STAT3 levels were re-
ported in a TLR2-deficient azoxymethane (AOM)-dextran 
sodium sulfate (DSS) murine model[82], while there were 
no differences in CAC between wild-type and TLR2-
deficient AOM-DSS colitic animals[83]. 
The pro-tumorigenic role of  TLR4 in CAC is well 
established. The intestinal microbiota, which normally 
colonize mucosal surfaces in symbiotic mutualism with 
the host is unique and quite stable over time[84]. The 
basic challenge for intestinal immune recognition is the 
requirement of  a simultaneous delicate balance between 
tolerance and responsiveness towards microbes[85]. Sev-
eral data suggest the existence of  immune tolerance to 
antigens in an individual’s bacterial flora, whereas its 
breakdown definitely contributes to IBD pathogenesis[86]. 
In the colon, where there is a constant interaction be-
tween microbiota and IECs, TLR4 deletion significantly 
reduces inflammation and tumor size in the AOM-DSS 
induced CAC-model in mice[87]. Additionally, overexpres-
sion of  the constitutively actived TLR4 exhibits a higher 
sensitivity to CAC in a transgenic mouse model[88]. Other 
studies[89,90] also support the results that both the deletion 
of  the TLR4 adaptor MyD88 molecule and the depletion 
of  TLR4 activating gut microbiome reduce colon cancer 
development. 
CONCLUSION
Inflammation affects many aspects of  tumorigenesis. 
One of  the important discoveries in the field of  TLR sig-
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naling and inflammation-associated cancer biology is the 
realization that TLRs may promote or suppress tumor 
formation in certain organs, including the intestine. 
Although recent data regarding the role of  TLRs 
in the pathomechanism of  CAC are rather conflicting, 
functionally they can be classified as “largely antitumoral” 
and “largely tumorigenic” molecules with the caveat that 
the underlying signaling pathways are mainly context, 
(i.e., organ-, tissue-, cell-) and ligand-dependent (Figure 
2). Advanced exploration and better understanding of  
the relationship amongst TLR-signaling, inflammatory 
microenvironment and colitis-associated carcinogenesis 
should provide further insight into cancer development 
in IBD patients. 
Further detailed functional analyses of  TLRs in in-
flammation-related tumor biology are needed to explore 
and define more precisely the subcellular and molecular 
mechanisms, hopefully allowing the introduction of  se-
lective new therapeutic approaches into daily practice.
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